Clinical trial · Observational
WB-DWI for Early Prediction of Therapy Response in Patients With Advanced Metastatic GIST Treated With Regorafenib
Whole Body Diffusion-weighted MRI (WB-DWI) for Early Prediction and Evaluation of Therapy Response in Patients With Advanced Metastatic Gastrointestinal Stromal Tumors (GIST) Treated With Regorafenib.
NCT01265979CI-TRIAL-00017445completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate WB DWI as early predictor of response to treatment with regorafenib or placebo in patients with advanced metastatic GIST.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastrointestinal Stromal Tumors | Gastrointestinal Stromal Tumor | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Whole body diffusion MRI | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- GIST treated with regorafenib/placebo
- description
- patients with advanced, metastatic gastro-intestinal stromal tumors treated with regorafenib or placebo
- interventionNames
- Procedure: Whole body diffusion MRI
Primary outcomes (1)
- measure
- WB-DWI as early predictor for regorafenib treatment response
- timeFrame
- jan 2011-dec 2011
- description
- Primary aim of the study: To assess whole body diffusion-weighted magnetic resonance imaging (WB-DWI) for the assessment and early prediction of response of treatment with regorafenib or placebo in patients with advanced, metastatic gastro-intestinal stromal tumors (GIST)
Secondary outcomes (1)
- measure
- Evaluation WB-DWI parameters in correlation with progression free survival (PFS)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * patients with advanced, metastatic gastro-intestinal stromal tumors treated with regorafenib or placebo Exclusion Criteria: * in case of a known contraindication for MRI (eg. pacemaker), the patient will not be admitted to the study
References
Publications (0)
Data not yet available
No reference posted for this study.